-
$100.00
BPC-157, or Body Protection Compound 157, is a synthetic peptide consisting of 15 amino acids. It is derived from a naturally occurring protective protein found in human gastric juice and has been extensively studied for its therapeutic potential. BPC-157 is renowned for its regenerative properties, with research indicating its ability to promote healing in various tissues, including muscles, tendons, ligaments, and the gastrointestinal tract, particularly in inflammatory conditions. Its broad biological effects have attracted significant interest in both scientific and medical communities as a promising candidate for treating injuries, chronic diseases, and inflammation-related disorders.
-
$59.00
BPC-157, or Body Protection Compound 157, is a synthetic peptide consisting of 15 amino acids. It is derived from a naturally occurring protective protein found in human gastric juice and has been extensively studied for its therapeutic potential. BPC-157 is renowned for its regenerative properties, with research indicating its ability to promote healing in various tissues, including muscles, tendons, ligaments, and the gastrointestinal tract, particularly in inflammatory conditions. Its broad biological effects have attracted significant interest in both scientific and medical communities as a promising candidate for treating injuries, chronic diseases, and inflammation-related disorders.
-
$56.00
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to elevate plasma levels of growth hormone and insulin-like growth factor 1 (IGF-1). The inclusion of a Drug Affinity Complex (DAC) extends the plasma half-life of CJC-1295, enhancing its stability and duration of action.
-
$200.00
Tirzepatide was originally developed to treat type 2 diabetes, but it has also demonstrated protective effects on the cardiovascular system. It is a synthetic analog of gastric inhibitory polypeptide (GIP) that also mimics the actions of glucagon-like peptide-1 (GLP-1). This dual mechanism helps reduce blood glucose levels, enhance insulin sensitivity, and promote a sense of satiety.
-
$275.00
Tirzepatide is a synthetic analog of gastric inhibitory polypeptide (GIP) that also exhibits glucagon-like peptide-1 (GLP-1) activity. This dual mechanism enables it to reduce blood glucose levels, enhance insulin sensitivity, and promote satiety. Originally developed for the treatment of type 2 diabetes, Tirzepatide has also demonstrated cardiovascular protective effects.
-
$350.00
Tirzepatide is a synthetic analog of gastric inhibitory polypeptide (GIP) that also exhibits glucagon-like peptide-1 (GLP-1) activity. This dual mechanism enables it to reduce blood glucose levels, enhance insulin sensitivity, and promote satiety. Originally developed for the treatment of type 2 diabetes, Tirzepatide has also demonstrated cardiovascular protective effects.
-
$400.00
Tirzepatide is a synthetic analog of gastric inhibitory polypeptide (GIP) that also exhibits glucagon-like peptide-1 (GLP-1) activity. This dual mechanism enables it to reduce blood glucose levels, enhance insulin sensitivity, and promote satiety. Originally developed for the treatment of type 2 diabetes, Tirzepatide has also demonstrated cardiovascular protective effects.
-
$255.00
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in glucose metabolism. As a GLP-1 receptor agonist, Semaglutide mimics the effects of endogenous GLP-1, promoting insulin secretion and suppressing glucagon release in a glucose-dependent manner—a mechanism that helps lower blood sugar without causing hypoglycemia.
-
$185.00
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in glucose metabolism. As a GLP-1 receptor agonist, Semaglutide mimics the effects of endogenous GLP-1, promoting insulin secretion and suppressing glucagon release in a glucose-dependent manner—a mechanism that helps lower blood sugar without causing hypoglycemia.
-
$100.00
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been primarily studied for the treatment of HIV-associated lipodystrophy, a condition characterized by abnormal fat distribution. Beyond this, ongoing research is exploring Tesamorelin’s potential to support peripheral nerve health, reduce fat mass, and slow the progression of mild cognitive impairment. These emerging applications suggest broader therapeutic value for Tesamorelin beyond its initial indication.
